AG-270
CAS No. 2201056-66-6
AG-270( —— )
Catalog No. M28586 CAS No. 2201056-66-6
AG-270 is an allosteric and orally active inhibitor of MAT2A.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 243 | Get Quote |
|
| 10MG | 389 | Get Quote |
|
| 25MG | 644 | Get Quote |
|
| 50MG | 888 | Get Quote |
|
| 100MG | 1233 | Get Quote |
|
| 500MG | 2457 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAG-270
-
NoteResearch use only, not for human use.
-
Brief DescriptionAG-270 is an allosteric and orally active inhibitor of MAT2A.
-
DescriptionAG-270 is an allosteric and orally active inhibitor of MAT2A.(In Vitro):AG-270 exhibits an IC50 of 20 nM in HCT116 MTAP-null cell SAM at 72 h.AG-270 demonstrates potent reduction in levels of intracellular SAM, as well as MTAP-null–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro.
-
In VitroAG-270 demonstrates potent reduction in levels of intracellular SAM, as well as MTAP-null–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro.AG-270 exhibits an IC50 of 20 nM in HCT116 MTAP-null cell SAM at 72 h.MAT2A is a key enzyme in the methionine salvage pathway, responsible for generating the universal methyl donor, S-adenosylmethionine (SAM).
-
In VivoAG-270 shows excellent microsomal, hepatocyte, and in vivo metabolic stability across species (human, mouse, rat, dog, and monkey). AG-270 exhibits T1/2 values of 5.9 h, 4.2 h, 4.8 h and 21.3 h in mouse, rat, monkey and dog, respectively.AG-270 (200 mg/kg, orally, q.d. for 38 days) results in dose-dependent reduction in tumor SAM levels and tumor growth of KP4 MTAP-null xenografts and is well tolerated, with mean body weight loss <5%.Combining AG-270 with taxanes and gemcitabine yielded additive-tosynergistic antitumor activity, with the docetaxel combination yielding 50% complete tumor regressions in select models; combination benefits are observed in PDX models derived from esophageal, NSCLC, and pancreatic cancers. Animal Model:Pancreatic KP4 MTAP-null xenograft mouse model.Dosage:10-200 mg/kg.Administration:Orally, q.d. for 38 days.Result:Led to dose-dependent reductions in tumor SAM levels and tumor growth of KP4 MTAP-null xenografts (TGI = 36% (10 mg/kg), 48% (30 mg/kg), 66% (100 mg/kg), 67% (200 mg/kg).
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2201056-66-6
-
Formula Weight489.57
-
Molecular FormulaC30H27N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (8.17 mM)
-
SMILESCOc(cc1)ccc1C(C(n1nc2-c3ccccc3)=O)=C(Nc3ncccc3)Nc1c2C1=CCCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bagalagel, Alaa A.; Bogari, Hanin A.; Ahmed, Safwat A.; Diri, Reem M.; Elhady, Sameh S.[Heterocycles, 2018, vol. 96, # 4, p. 749 - 756]
molnova catalog
related products
-
KKI-5 (TFA)
KKI-5 (TFA) is a specific tissue kallikrein inhibitor.Kki-5 (TFA) can reduce breast cancer cell infiltration.
-
K03861
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
-
Lactic acid
Lactic acid (2-hydroxypropanoic acid) is a product of glycolysis and is widely found in nature.Lactic acid is produced in the body during hypoxia in contracted skeletal muscle and can be removed under fully aerobic conditions.
Cart
sales@molnova.com